Hey there! Welcome!
Get updated on
Select Speciality
Top Picks
3 Feb, 26
This IDSA guideline outlines evidence‑based empiric and definitive antibiotic selection for complicated UTI, emphasizing severity‑based therapy, resistance risk assessment, patient‑specific factors, and stewardship‑driven narrowing once cultures return.
3 Feb, 26
9 Feb, 26
Respir Med
- COPD and heart failure frequently coexist but remain undiagnosed
- In specialized clinics, unrecognized HF in COPD was 26.1%, and unrecognized COPD in HF was 26.8% and these patients were older, mostly male, and heavy smokers
- Abnormal echocardiography/spirometry increased exacerbation like events (1.3 vs 0.6 in COPD; 16.7% vs 6.3% in HF)
- No specific biomarkers reliably distinguished overlap disease.
5 Feb, 26J. Eur. Acad. Dermat...
- As per a systematic review & meta-analysis of 90 studies of adjunctive therapy for T1DM, GLP 1RAs lowered HbA1c (−0.56%), body weight (−3.6 kg), BMI (−1.05 kg/m²), & insulin use, with rare severe hypoglycemia/DKA but frequent GI effects
- SGLT2is improved HbA1c (−0.38%), TIR (+8.6 pp), insulin (−4.7 U/day), weight (−2.5 kg), BMI (−0.82 kg/m²), but doubled DKA risk (RR=2.19)
- Mortality/hospitalizations were rare.
5 Feb, 26BMC Gastroenterol.
- A study of 13,208 children with intermittent asthma found a distinct low‑risk subgroup with very low rates of severe exacerbations
- Over three years, these patients had far fewer hospitalizations and emergency visits than higher risk peers
- For this group, routine inhaled corticosteroid treatment offered minimal benefit and was not cost effective, suggesting current mild asthma guidelines may overtreat them.
4 Feb, 26J Neurol.
- In 250 obese adults with T1DM (BMI ≥27 kg/m2, 54.8% female), tirzepatide (n=35), semaglutide (n=36), & liraglutide (n=97) produced 12 mth weight loss of 10.9% (p<0.001), 9.9% (p<0.001), & 7.1% (p<0.001), vs no change in usual care (n=82)
- HbA1c fell by 0.65%, 0.33%, & 0.23%, resp, semaglutide & liraglutide lowered LDL (p=0.05, p=0.02); liraglutide reduced UACR (p=0.007)
- No severe hypoglycemia or DKA occurred.
5 Feb, 26
Featured
Key Trials
23 Jan, 26
23 Jan, 26
23 Jan, 26
22 Jan, 26
